Fleischer L, Kirchhoff H, Schoenherr C, Heidenreich O, Scherr M, Eder M. Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia. haematol [Internet]. 2020Sep.10 [cited 2026Jul.9];. Available from: https://haematologica.org/article/view/14257